Central and East European Oncology Group

  • Members
    Members

    CEEOG has greatly expanded and now includes 35 academic andcommunity hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia.

     

     

     

Polish Brain Metastasis Consortium

pbmc-logo

The group was founded in 2005 by Dr. Renata Duchnowska from the Military Medical Institute in Warsaw as a result of establishing an informal network of some Polish oncology centers. A year later group teamed up with foreign research groups and academic centers. In 2008, the patronage of the Group's research covered the CEEOG.

FLIKER

Study Team

Study Chair: Ewa Szutowicz-Zielińska, MD, PhD

Medical Advisor: Rafał Dziadziuszko, MD, PhD

Study Statistician: Tomasz Burzykowski, PhD

Study Coordinator: Anna Brociek, MSc

Protocol

CEEOG 0106/ML20033

Study title

An open label phase II study evaluating the effectiveness of first line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients selected by positive FISH EGFR test (FLIKER)

Study start date

December 12, 2007

Study status

Open

Study design

A multicenter, open-label, single-arm phase II clinical trial. NSCLC patients who are chemo-naive are registered for screening (EGFR gene copy number by FISH). Upon positive test, patients are included in the study and treated with erlotinib until disease progression, unacceptable toxicity or withdrawn consent. Continuous oral erlotinib is given once daily at a dose of 150 mg. Dose reductions are permitted and based on tolerability to drug therapy. Patients with negative test are offered the best available treatment (most often chemotherapy or palliative radiotherapy) or best supportive care according to the decision of their primary physician.

Sample size

72 patients

Study objectives

The primary objective of this study:

The primary objective of the trial is to determine the efficacy (as measured by the proportion of patients alive and free of progression at 12 months after study entry) of EGFR TKI inhibitor erlotinib in first line treatment of advanced NSCLC patients selected by positive FISH EGFR.

The secondary objective of this study:

To assess the response rate, overall survival, and clinical benefit proportion.

To perform exploratory molecular studies of other markers predicting response and survival benefit from erlotinib.

Patient population

Patients must meet all of the following inclusion criteria to be eligible for participation in this program.

Inclusion Criteria:

  • histologically confirmed NSCLC

  • stage IIIB with pleural effusion or stage IV at study entry

  • paraffin-embedded tumor sample available for sensitivity analysis (microscopic diagnosis only by cytology renders the patient ineligible for this trial

  • measurable tumor according to RECIST criteria

  • Age > 18 years

  • WHO Performance Status 0 - 2

  • Adequate liver and renal function (ALT < 2,5 UNL or ALT < 5 ULN in patients with liver metastases, bilirubin within normal limits, creatinine < 1.5 ULN) and adequate haematology (haemoglobin >11 g/dL, WBC>2.000/µL, PLT>100.000/µL)

  • Patients of reproductive potential must use adequate contraception

  • No previous systemic anticancer treatment. Previous radiotherapy is allowed provided marker lesions are outside the irradiated volume

  • No histological diagnosis of SCLC or mixed NSCLC/SCLC type

  • Stable medical conditions (e.g. no psychotic disorders, drug abuse, active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within 12 months, hepatic or renal insufficiency)

  • No history of malignancy diagnosed within last 5 years prior to enrollment other than basal-cell skin cancer or in situ cervical cancer

  • No participation in any investigational study within 30 days prior to enrollment

  • No pregnancy or lactation

  • No known hypersensitivity to erlotinib or to any of the excipients

  • Written informed consent

  • Positive EGFR FISH test defined as: high level of polysomy (≥4 copies of the gene in ≥40% of cells) or gene amplification, defined by presence of tight gene clusters and a ratio gene/chromosome per cell ≥2, or ≥15 copies of the genes per cell in ≥10% of analyzed cells.

Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be undimensionally measurable as follows: Spiral CT scan > 10 mm, Non-spiral CT scan > 20 mm.

List of Sites participating in the study

No

Center and addresss

Date of Site Initiation Visit

1

Dr Ewa Szutowicz- Zielińska
Klinika Onkologii I Radioterapii
ul. Debinki 7 80-211 Gdańsk

12/12/2007

2

Dr Sergiusz Nawrocki
Zakład Radioterapii ZOZ MSW
Warmińsko- Mazurskie Centrum Onkologii
ul. Wojska Polskiego 37 10-228 Olsztyn

30/01/2008

3

Dr Marcin Murmyło
Dolnośląskie Centrum Chorób Płuc
ul. Grabiszyńska 105
53-439 Wrocław

20/11/2008

4

Dr Kazimierz Drosik
Oddział Onkologii KlinicznejOpolskie
Centrum Onkologiiul.
Katowicka 66a45-060 Opole

15/01/2008

5

Dr Aleksandra Szczęsna
Oddział III Chorób Płucul
.Reymonta 83/9105-400 Otwock

09/05/2008

6

Prof. Cezary Szczylik
Klinika Onkologiiul
Szaserów 12804-141 Warszawa

24/02/2009

7

Dr Andrzej Każarnowicz
Oddział V Chemioterapii Nowotworów Płuc
Samodzielny Publiczny Zespół Gruźlicy i Chorób Płucul.
Jagielońska 7810-357 Olsztyn

08/09/2009

CONTACT

Home
 
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland 
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie obsługi JavaScript.